Hisato Kawakami

All Stories

1. 
   Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

2. 
   Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

3. 
   Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

4. 
   Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

5. 
   Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

6. 
   Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

7. 
   Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

8. 
   Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

9. 
   Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

   Article • August 2023, American Association for Cancer Research (AACR)

   Hisato Kawakami

10. 
    Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

11. 
    Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

12. 
    Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

13. 
    Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

14. 
    Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

15. 
    Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

16. 
    Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

17. 
    Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

18. 
    Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

19. 
    Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

20. 
    Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

21. 
    Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

22. 
    Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

23. 
    Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

24. 
    Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

25. 
    Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)

    Article • International Journal of Clinical Oncology, July 2023, Springer Science + Business Media

    Hisato Kawakami

26. 
    Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

    Article • Nature Communications, June 2023, Springer Science + Business Media

    Hisato Kawakami

27. 
    Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial

    Article • European Journal of Cancer, May 2023, Elsevier

    Hisato Kawakami

28. 
    The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

    Article • Scientific Reports, April 2023, Springer Science + Business Media

    Hisato Kawakami

29. 
    Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

30. 
    Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

31. 
    Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

32. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

33. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

34. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

35. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

36. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

37. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

38. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

39. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

40. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

41. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

42. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

43. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

44. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

45. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

46. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

47. 
    Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

48. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

49. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

50. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

51. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

52. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

53. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

54. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

55. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

56. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

57. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

58. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

59. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

60. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

61. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

62. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

63. 
    Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

64. 
    Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

65. 
    Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

66. 
    Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

67. 
    Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

68. 
    Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

69. 
    Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • March 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

70. 
    Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

    Article • Journal of Clinical Oncology, February 2023, American Society of Clinical Oncology (ASCO)

    Hisato Kawakami

71. 
    Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

    Article • Esophagus, January 2023, Springer Science + Business Media

    Hisato Kawakami

72. 
    Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

    Article • Esophagus, December 2022, Springer Science + Business Media

    Hisato Kawakami

73. 
    Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

    Article • Cancers, November 2022, MDPI AG

    Hisato Kawakami

74. 
    Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy

    Article • BMC Cancer, July 2022, Springer Science + Business Media

    Hisato Kawakami

75. 
    Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer

    Article • Cancer Science, July 2022, Wiley

    Hisato Kawakami

76. 
    Sequential treatment strategy using fluoropyrimidine plus bevacizumab followed by oxaliplatin for metastatic colorectal cancer: A phase II study (OGSG 1107)

    Article • Gastrointestinal Tumors, February 2022, Karger Publishers

    Hisato Kawakami

77. 
    HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • Clinical Cancer Research, December 2021, American Association for Cancer Research (AACR)

    Hisato Kawakami

78. 
    Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201

    Article • European Journal of Cancer, September 2021, Elsevier

    Hisato Kawakami

79. 
    KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

    Article • Clinical Cancer Research, August 2021, American Association for Cancer Research (AACR)

    Hisato Kawakami

80. 
    Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis

    Article • Molecular Oncology, July 2021, Wiley

    Hisato Kawakami

81. 
    Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb‐202 in gastric cancer

    Article • Clinical and Translational Medicine, June 2021, Wiley

    Hisato Kawakami

82. 
    An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

    Article • Cancers, February 2021, MDPI AG

    Hisato Kawakami

83. 
    Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model

    Article • Journal of Clinical Medicine, December 2020, MDPI AG

    Hisato Kawakami

84. 
    Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

    Article • British Journal of Cancer, December 2020, Springer Science + Business Media

    Hisato Kawakami

85. 
    A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood

    Article • Case Reports in Oncology, July 2020, Karger Publishers

    Hisato Kawakami

86. 
    Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105...

    Article • International Journal of Clinical Oncology, June 2020, Springer Science + Business Media

    Hisato Kawakami

87. 
    Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance

    Article • Cancers, February 2020, MDPI AG

    Hisato Kawakami

88. 
    U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

    Article • Journal of Clinical Investigation, December 2019, American Society for Clinical Investigation

    Hisato Kawakami, Masaaki Miyazawa

89. 
    Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

    Article • Oncogenesis, September 2019, Springer Science + Business Media

    Hisato Kawakami

90. 
    [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

    Article • International Journal of Cancer, May 2019, Wiley

    Hisato Kawakami

91. 
    Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial

    Article • The Oncologist, August 2018, Alphamed Press

    Hisato Kawakami

92. 
    Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer

    Article • Investigational New Drugs, April 2018, Springer Science + Business Media

    Hisato Kawakami

93. 
    Abstract 2173: Targeting CDK1 and MEK/ERK overcome mutant BRAF-mediated apoptosis resistance in human colorectal cancer cells

    Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

    Hisato Kawakami

94. 
    Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer

    Article • Oncotarget, May 2017, Impact Journals, LLC

    Hisato Kawakami

95. 
    Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

    Article • Investigational New Drugs, March 2017, Springer Science + Business Media

    Hisato Kawakami

96. 
    Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer

    Article • Molecular Cancer Therapeutics, December 2016, American Association for Cancer Research (AACR)

    Hisato Kawakami

97. 
    Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

    Article • Oncotarget, October 2016, Impact Journals, LLC

    Hisato Kawakami

98. 
    HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy

    Article • Recent Patents on Anti-Cancer Drug Discovery, August 2016, Bentham Science Publishers

    Hisato Kawakami

99. 
    Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer

    Article • Clinical Gastroenterology and Hepatology, May 2016, Elsevier

    Hisato Kawakami

100. 
     Sa1808 Mutant BRAF (V600E) Phosphorylates MCL-1 to Increase Stability/Expression That Confers Apoptosis Resistance in Colorectal Cancer Cells

     Article • Gastroenterology, April 2016, Elsevier

     Hisato Kawakami

101. 
     Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

     Article • Investigational New Drugs, March 2016, Springer Science + Business Media

     Hisato Kawakami

102. 
     MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy

     Article • Gastric Cancer, December 2015, Springer Science + Business Media

     Hisato Kawakami

103. 
     Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer

     Article • Cancer Chemotherapy and Pharmacology, June 2015, Springer Science + Business Media

     Hisato Kawakami

104. 
     Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer

     Article • Current Treatment Options in Oncology, June 2015, Springer Science + Business Media

     Hisato Kawakami

105. 
     49 Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Bcl-xL Antagonism and Induction of Pro-Apoptotic BH3-Only Proteins in Colorectal Carcinoma Cells

     Article • Gastroenterology, April 2015, Elsevier

     Hisato Kawakami

106. 
     Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells

     Article • Molecular Cancer Research, April 2015, American Association for Cancer Research (AACR)

     Hisato Kawakami

107. 
     The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

     Article • Oncotarget, December 2014, Impact Journals, LLC

     Hisato Kawakami

108. 
     Targeting MET Amplification as a New Oncogenic Driver

     Article • Cancers, July 2014, MDPI AG

     Hisato Kawakami

109. 
     Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

     Article • PLoS ONE, July 2014, PLOS

     Hisato Kawakami

110. 
     Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

     Article • Investigational New Drugs, May 2014, Springer Science + Business Media

     Hisato Kawakami

111. 
     Human papillomavirus DNA and p16 expression in J apanese patients with oropharyngeal squamous cell carcinoma

     Article • Cancer Medicine, October 2013, Wiley

     Hisato Kawakami

112. 
     Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

     Article • European Journal of Cancer, September 2013, Elsevier

     Hisato Kawakami

113. 
     Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer.

     Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

     Hisato Kawakami

114. 
     MET amplification as a potential therapeutic target in gastric cancer

     Article • Oncotarget, November 2012, Impact Journals, LLC

     Hisato Kawakami

115. 
     Human Epidermal Growth Factor Eyedrops for Cetuximab-Related Filamentary Keratitis

     Article • Journal of Clinical Oncology, August 2011, American Society of Clinical Oncology (ASCO)

     Hisato Kawakami

116. 
     Lemierre's Syndrome with Acute Renal Failure

     Article • Nihon Naika Gakkai Zasshi, January 2007, Japanese Society of Internal Medicine

     Hisato Kawakami